Artiklar med krav på offentlig åtkomst - Nabil SeidahLäs mer
Inte tillgängliga någonstans: 27
PCSK9 as a therapeutic target of dyslipidemia
NG Seidah
Expert opinion on therapeutic targets 13 (1), 19-28, 2009
Krav: Canadian Institutes of Health Research
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
M Abifadel, M Guerin, S Benjannet, JP Rabès, W Le Goff, Z Julia, ...
Atherosclerosis 223 (2), 394-400, 2012
Krav: Canadian Institutes of Health Research, National Institute of Health and …
The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography
Z Awan, M Denis, D Bailey, A Giaid, A Prat, D Goltzman, NG Seidah, ...
Atherosclerosis 219 (2), 455-462, 2011
Krav: Canadian Institutes of Health Research
Reducing vascular calcification by anti-IL-1β monoclonal antibody in a mouse model of familial hypercholesterolemia
Z Awan, M Denis, A Roubtsova, R Essalmani, J Marcinkiewicz, A Awan, ...
Angiology 67 (2), 157-167, 2016
Krav: Canadian Institutes of Health Research
Proprotein convertases as therapeutic targets
M Chrétien, NG Seidah, A Basak, M Mbikay
Expert opinion on therapeutic targets 12 (10), 1289-1300, 2008
Krav: Canadian Institutes of Health Research
New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications
NG Seidah
Current Opinion in Lipidology 27 (3), 274-281, 2016
Krav: Canadian Institutes of Health Research, Leducq Foundation, USA
Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype
Z Awan, EE Delvin, E Levy, J Genest, J Davignon, NG Seidah, A Baass
Canadian Journal of Cardiology 29 (8), 927-933, 2013
Krav: Canadian Institutes of Health Research
SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection
M Blanchet, C Sureau, C Guévin, NG Seidah, P Labonté
Antiviral research 115, 94-104, 2015
Krav: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé …
Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
ML Peyot, A Roubtsova, R Lussier, A Chamberland, R Essalmani, ...
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2021
Krav: Canadian Institutes of Health Research, Natural Sciences and Engineering …
The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and …
NG Seidah, M Chrétien, M Mbikay
Current opinion in lipidology 29 (2), 144-150, 2018
Krav: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Viral envelope glycoprotein processing by proprotein convertases
A Pasquato, JR da Palma, C Galan, NG Seidah, S Kunz
Antiviral research 99 (1), 49-60, 2013
Krav: Swiss National Science Foundation
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
S Elbitar, PE Khoury, Y Ghaleb, JP Rabès, M Varret, NG Seidah, ...
Expert Opinion on Therapeutic Patents 26 (12), 1377-1392, 2016
Krav: National Institute of Health and Medical Research, France, Leducq Foundation …
Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells
N Denis, H Palmer-Smith, F Elisma, A Busuttil, TG Wright, MB Khalil, ...
Journal of proteome research 10 (4), 2011-2026, 2011
Krav: Canadian Institutes of Health Research
Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone
B Hoac, D Susan-Resiga, R Essalmani, E Marcinkiweicz, NG Seidah, ...
Bone 107, 45-55, 2018
Krav: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé …
Association between plasma proprotein convertase subtilisin/kexin type 9 and the presence of metabolic syndrome in a predominantly rural-based sub-Saharan African population
M Paquette, YG Luna Saavedra, A Chamberland, A Prat, DL Christensen, ...
Metabolic syndrome and related disorders 15 (8), 423-429, 2017
Krav: Canadian Institutes of Health Research, Leducq Foundation, USA
A single domain antibody against the Cys-and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice
R Essalmani, E Weider, J Marcinkiewicz, A Chamberland, ...
Biological Chemistry 399 (12), 1363-1374, 2018
Krav: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Statins can exert dual, concentration dependent effects on HCV entry in vitro
M Blanchet, QT Le, NG Seidah, P Labonté
Antiviral Research 128, 43-48, 2016
Krav: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by …
MS Gauthier, Z Awan, A Bouchard, J Champagne, S Tessier, D Faubert, ...
Journal of clinical lipidology 12 (4), 1027-1038, 2018
Krav: US National Institutes of Health, Canadian Institutes of Health Research …
A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease
M Di Filippo, B Vokaer, NG Seidah
Journal of clinical lipidology 11 (4), 1101-1105, 2017
Krav: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
NG Seidah
Nature Structural & Molecular Biology 24 (10), 785-786, 2017
Krav: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Publikations- och finansieringsuppgifter tas fram automatiskt av ett datorprogram.